research The Relevance of Collagen XVII Expression in Epidermal Differentiation and Proliferation
Collagen XVII is crucial for skin cell growth and nail health.
Search
for
Sort by
Research
240-270 / 778 results 
research PRIDE Syndrome Associated With Panitumumab Treatment – Case Report and Literature Review
A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
research Topical Application of Aprepitant Inhibits Erlotinib-Induced Facial Dermatitis and Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research Classification and Management of Skin, Hair, Nail, and Mucosal Side Effects of Epidermal Growth Factor Receptor Inhibitors
EGFR inhibitors often cause skin problems and other side effects, but these are usually reversible and can be managed to keep patients comfortable.
research Arrow Sign: A Rapid Microscopic Diagnosis of Hair Change Associated with Epidermal Growth Factor Receptor Inhibitors
A new method quickly detects hair changes from EGFR inhibitors using a microscope.
research The Epithelial Stem Cell Niche in Skin
Skin's epithelial stem cells are crucial for repair and maintenance, and understanding them could improve treatments for skin problems.
research Dermatologic Adverse Events Associated With Afatinib: An Oral ErbB Family Blocker
Afatinib often causes skin problems that need proactive management.
research Cutaneous Adverse Events to Systemic Antineoplastic Therapies: A Retrospective Study in a Public Oncologic Hospital
Skin side effects from cancer treatments can lead to changes in therapy and are common, with nail changes being the most frequent.
research Proceedings of the Heinz Maurer-Symposium: Review and Preview in Science for Healthy Skin, June 28, 2014, Jakobsberg, Boppard, Germany
The symposium concluded that environmental factors significantly contribute to skin aging.
research The PRIDE Syndrome: Dermatological Side Effects of EGFR Inhibitors
PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
research Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
research Folliculitis Decalvans-Like Alopecia During EGFR Inhibitors Treatment for Lung Cancer: A Case Series of 6 Patients
Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.
research Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor
Cetuximab often causes skin problems, but they can be managed without stopping treatment.
research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
research Trichomegaly of the Eyelashes Following Treatment with Cetuximab
Cetuximab can cause excessive eyelash growth.
research An Overview of Management of Drug-Induced Hair and Nail Disorders
Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.
research Salt-Losing Tubulopathy and Chronic Dermatitis
Genetic testing for EGFR mutations is crucial in similar cases.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Semiology of Skin Toxicity Associated with Epidermal Growth Factor Receptor Inhibitors
Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
research Mario Lacouture: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
A cancer patient died from a severe skin reaction after taking the drug cetuximab.
research Cetuximab-Associated Elongation of the Eyelashes
Cetuximab can cause eyelash growth, which is rare but manageable.
research A Novel Approach to Manage Skin Toxicity Caused by Therapeutic Agents Targeting Epidermal Growth Factor Receptor
New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
research Management of Dermatologic Toxicities
Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
research Successful Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Alopecia with Doxycycline
Doxycycline can effectively treat hair loss caused by EGFR inhibitors.
research KGF And EGF Signaling Block Hair Follicle Induction And Promote Interfollicular Epidermal Fate In Developing Mouse Skin
EGF and KGF signalling prevent hair follicle formation and promote skin cell development in mice.
research Taiwanese Dermatological Association Consensus for the Prevention and Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Related Skin Toxicities
The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
research Scarring Alopecia Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Dermatologic Reactions to Targeted Therapy
Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.